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Abstract
Objective: To systematically review and meta-analyze published data about the diagnostic
performance of Fluorine-18-Fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and
PET/computed tomography (PET/CT) in patients with chronic inflammatory bowel disease (IBD).
Methods: A comprehensive computer literature search of studies published through May 2012
regarding 18F-FDG-PET and PET/CT in patients with IBD was performed. All retrieved studies
were reviewed and qualitatively analyzed. Pooled sensitivity, specificity, positive and negative
likelihood ratio (LR+ and LR−) and diagnostic odd ratio (DOR) of 18F-FDG PET and PET/CT in
patients with IBD on a per segment-based analysis were calculated. The area under the ROC
curve was calculated to measure the accuracy of 18F-FDG PET and PET/CT in patients with IBD.
Results: Nineteen studies comprising 454 patients with suspected IBD were included in the
qualitative analysis (systematic review) and discussed. The quantitative analysis (meta-analysis)
of seven selected studies (including 219 patients with IBD) provided the following results on a per
segment-based analysis: sensitivity was 85% [95% confidence interval (95%CI) 81–88%],
specificity 87% (95%CI 84–90%), LR+ 6.19 (95%CI: 2.86–13.41), LR− 0.19 (95%CI: 0.10–0.34), and
DOR 44.35 (95%CI: 11.77–167.07). The area under the ROC curve was 0.933.of Nuclear Medicine, Catholic University of the Sacred Heart, Largo Gemelli, 8, 00168, Rome, Italy.
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346 G. Treglia et al.Conclusions: In patients with suspected IBD 18F-FDG PET and PET/CT demonstrated good
sensitivity and specificity, being accurate methods in this setting. Nevertheless, the literature
focusing on the use of PET and PET/CT in IBD remains still limited; thus, further large
multicenter studies will be necessary to substantiate the diagnostic accuracy of these methods
in patients with IBD.
© 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.Contents
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The diagnosis of chronic inflammatory bowel disease (IBD) is
usually performed by a combination of data obtained by a
detailed patient history, physical examination, laboratory
tests, radiologic studies (including CT, magnetic resonance
imaging [MRI], ultrasonography [US]), and endoscopic
evaluation.1,2 A challenge for the clinicians in managing
IBD is determining whether symptoms are related to the
inflammation in the intestinal tract. Therefore, a noninva-
sive test able to detect active inflammation in the intestinal
tract may be useful in the evaluation and management
of IBD.2,3
Fluorine-18-Fluorodeoxyglucose (18F-FDG) positron emis-
sion tomography (PET) and PET/computed tomography
(PET/CT) have been proposed as noninvasive imaging
methods to assess extent, location, and disease activity in
patients with IBD. 18F-FDG PET allows the identification of
areas of increased metabolic activity by measuring the
uptake of 18F-FDG, a glucose analogue, both in inflammatory
diseases and in malignancies. In fact, not only neoplastic
cells but also inflammatory cells, such as neutrophils and
macrophages, may accumulate high levels of 18F-FDG.2,4,5
Moreover, hybrid PET/CT device allows enhanced detec-
tion and characterization of abnormal intestinal findings, by
combining the functional data obtained from 18F-FDG PET
with morphological data obtained from CT.6,7
Several studies have evaluated 18F-FDG PET and PET/CT
in assessing IBD, reporting different values of sensitivityand specificity in this setting. The purpose of our study is
to systematically review and meta-analyze published data
on the diagnostic performance of 18F-FDG PET or PET/CT in
patients with suspected IBD.2. Methods
Our meta-analysis was performed according to the “Preferred
Reporting Items for Systematic Reviews and Meta-Analyses”
(PRISMA) statement which describes an evidence-based
minimum set of items for reporting in systematic reviews and
meta-analyses.82.1. Search strategy
A comprehensive computer literature search of the PubMed/
MEDLINE, Embase and Scopus databases was conducted to
find relevant published articles on the diagnostic perfor-
mance of 18F-FDG-PET and PET/CT in patients with IBD. We
used a search algorithm that was based on a combination of
the terms: a) “PET” OR “positron emission tomography” AND
b) “IBD” or “inflammatory bowel disease” or “Crohn” or
“ulcerative colitis”. No beginning date limit was used; the
search was updated until May 31st, 2012. No language
restriction was used. To expand our search, references of
the retrieved articles were also screened for additional
studies.
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Studies or subsets in studies investigating the diagnostic
performance of 18F-FDG PET or PET/CT in patients with IBD
were eligible for inclusion. The exclusion criteria were:
a) articles not within the field of interest of this review;
b) review articles, editorials or letters, comments, conference
proceedings; c) case reports or small case series; d) overlap
in patient data (duplicate publication; in such cases the most
complete article was included).
For the quantitative analysis (meta-analysis) we also
excluded studies with insufficient data to reassess sensitivity
or specificity.
Three researchers (GT, NQ and AC) independently
reviewed the titles and abstracts of the retrieved articles,
applying the inclusion and exclusion criteria mentioned
above. Articles were rejected if they were clearly ineligible.
The same three researchers then independently reviewed
the full-text version of the remaining articles to determine
their eligibility for inclusion. Disagreements were resolved in
a consensus meeting.
2.3. Data extraction
For each included study, information was collected concerning
basic study (authors, year of publication, country of origin,
study design), patient characteristics (mean age, sex, number
of patients with IBD, type of IBD), technical aspects (device
used, radiopharmaceutical injected dose, time between
18F-FDG injection and image acquisition, image analysis,
applied reference standard) and other imaging methods
performed. For each study the number of true positive, false
positive, true negative and false negative findings for 18F-FDG
PET and PET/CT in diagnosis of IBD was recorded on a per
segment-based analysis.
2.4. Quality assessment
The 2011 Oxford Center for Evidence-Based Medicine checklist
for diagnostic studies was used for quality assessment of
the included studies.9 This checklist has 5 major parts as
follows:
1. Representative spectrum of the patients
2. Consecutive patient recruitment
3. Ascertainment of the gold standard regardless of the index test
results
4. Independent blind comparison between the gold standard and
index test results
5. Enough explanation of the test to permit replication.
2.5. Statistical analysis
Sensitivity and specificity, positive and negative likelihood
ratio (LR+ and LR−) and diagnostic odd ratio (DOR) of
18F-FDG PET and PET/CT in patients with IBD was obtained
from individual studies on a per segment-based analysis.
A random effect model was used for statistical pooling of
the data. Pooled data were presented with 95% confidence
intervals (95%CI). A I-square index was used to test for
heterogeneity between studies. The area under the ROCcurve was calculated to measure the accuracy of 18F-FDG
PET or PET/CT in patients with IBD. For publication bias
evaluation, funnel plots were used. Statistical analyses
were performed using Meta-DiSc statistical software version
1.4 (Unit of Clinical Biostatistics, Ramón y Cajal Hospital,
Madrid, Spain).10
3. Results
3.1. Literature search
The comprehensive computer literature search from
PubMed/MEDLINE, Embase and Scopus databases revealed
104 articles. Reviewing titles and abstracts, 85 articles were
excluded: 46 because not in the field of interest of this
review, 26 as reviews or editorials, and 13 as case reports.
Nineteen articles were selected and retrieved in full-text
version11–29; no additional study was found screening the
references of these articles. From these 19 articles (includ-
ing 454 patients with IBD) eligible for the qualitative analysis
(systematic review), after reviewing the full-text article, 12
articles were excluded from the quantitative analysis
(meta-analysis) due to insufficient data to calculate sensi-
tivity or specificity of 18F-FDG PET and PET/CT on a per
segment-based analysis.11,14,16,18–24,26,28 Finally, seven
studies, comprising a total sample size of 219 patients with
suspected IBD met all inclusion and exclusion criteria, and they
were included in our meta-analysis (Fig. 1).12,13,15,17,25,27,29
The characteristics of the included studies are presented in
Tables 1–2.
3.2. Qualitative analysis (systematic review)
Using the database search, 19 complete articles written
over the past 15 years were found; most of them were
prospective studies. Fifteen studies evaluated adult
patients,11,13,16–26,28,29 whereas the remaining four articles
included pediatric patients (Table 1).12,14,15,27
Thirteen studies used hybrid PET/CT device to evaluate
patients with IBD,16–28 whereas six studies used PET imaging
alone.11–15,29 Nevertheless, heterogeneous technical aspects
between the included studies were found (Table 2).
The PET image analysis was usually performed by using
qualitative and semi-quantitative criteria, the latter based
on the calculation of standardized uptake values (SUV) of
the bowel segments. Furthermore, the images were often
analyzed using a 4-point scale taking the liver activity as a
reference. A score of 0 corresponded to an activity of
the bowel segment lower than the liver, 1 was equal to the
liver, 2 and 3 were more active than the liver and considered
as positive for active inflammation by most of the authors.
Some authors compared the radiopharmaceutical uptake in
the bowel segments to the spine (as reference region).12,14
The reference standard used and the other imaging
modalities performed in the included studies were quite
different (Tables 2 and 3). Table 3 shows the results of the
quality assessment of the studies included in this systematic
review.
18F-FDG PET and PET/CT demonstrated to be noninvasive
tools for the assessment of patients with IBD11–29 also if there
is still limited evidence on these imaging methods in IBD.
Table 1 basic study and patient characteristics.
Authors Year Country Study design Patients performing
18F-FDG PET or PET/CT
Mean age
(years)
%Male Type of IBD
Holtmann et al.29 2012 Germany Prospective 43+6 controls 36.2 49% 43 CD
Lenze et al.28 2012 Germany Prospective 30 35 43% 30 CD
Däbritz et al.27 2011 Germany Retrospective 45 13.2 60% 35 CD, 10 UC
Lapp et al.26 2011 USA Prospective 7 56.8 86% 4 CD, 2 UC
Shyn et al.25 2010 USA Prospective 13 48.5 31% 13 CD
Ahmadi et al.24 2010 USA Retrospective 41 40 73% 41 CD
Das et al.23 2010 India Prospective 15+10 controls 38.7 47% 15 UC
Spier et al.22 2010 USA Prospective 5 42 100% 3 CD, 2 UC
Groshar et al.21 2010 Israel Prospective 28 37.5 39% 28 CD
Jacene et al.20 2009 USA Prospective 17 39 47% 17 CD
Rubin et al.19 2009 USA Prospective 10 60 60% 10 UC
Das et al.18 2007 India Prospective 17 33.7 59% 9 CD
Louis et al.17 2007 Belgium Prospective 22 32.5 32% 22 CD
Meisner et al.16 2007 USA Prospective 12+20 controls 44.7 75% 7 CD, 5 UC
Löffler et al.15 2006 Germany Retrospective 23 12 56% 17 CD, 2 UC
Lemberg et al.14 2005 Canada Prospective 65 13.3 58% 38 CD, 17 UC
Neurath et al.13 2002 Germany Prospective 59+32 controls 37.5 36% 59 CD
Skehan et al.12 1999 Canada NR 25 13 36% 15 CD, 3 UC
Bicik et al.11 1997 Switzerland Prospective 7 NR NR 5 CD, 2 UC
Legend: NR: not reported; IBD: inflammatory bowel disease; CD: Crohn's disease; and UC: ulcerative colitis.
Figure 1 Flow chart of the search for eligible studies on the diagnostic performance of 18F-FDG PET and PET/CT in patients
with IBD.
348 G. Treglia et al.
Table 2 Technical aspects of 18F-FDG PET and PET/CT in the included studies.
Authors Device 18F-FDG mean
injected dose
Time between 18F-FDG
injection and image
acquisition
Image analysis Other imaging methods
performed
Holtmann et al.29 PET 325 MBq 60 min Visual and semi-quantitative
(uptake compared to liver)
Endoscopy, hydro-MRI
Lenze et al.28 PET/CT 4 MBq/kg 60 min Visual and semi-quantitative
(uptake compared to liver)
Endoscopy, MR enteroclysis,
abdominal ultrasonography
Däbritz et al.27 PET and
PET/CT
3 MBq/kg 60 min Visual (uptake compared
to liver)
Endoscopy, abdominal
ultrasonography
Lapp et al.26 PET/CT 5.18 MBq/kg 50 min Visual and semiquantitative
(uptake compared to liver)
Endoscopy, CT enterography,
and small bowel imaging
Shyn et al.25 PET/CT 300 MBq 57–94 min Visual and semiquantitative CT enterography, endoscopy
Ahmadi et al.24 PET/CT 5.28 MBq/kg 90 min Visual and semiquantitative CT enterography
Das et al.23 PET/CT 370 MBq 60 min Visual and semiquantitative
(uptake compared to liver)
CT colonography, endoscopy
Spier et al.22 PET/CT 370 MBq 50 min Visual (uptake compared
to liver)
Endoscopy
Groshar et al.21 PET/CT 185 MBq NR Visual and semiquantitative CT enterography, endoscopy
Jacene et al.20 PET/CT 8.14 MBq/kg 60 min Visual and semiquantitative Endoscopy
Rubin et al.19 PET/CT 370 MBq 60 min Visual (uptake compared
to liver)
Endoscopy
Das et al.18 PET/CT 370 MBq 60 min Visual and semiquantitative
(uptake compared to liver)
CT enteroclysis, small bowel
follow through, endoscopy
Louis et al.17 PET/CT 3.7 MBq/kg 60 min Visual and semiquantitative
(uptake compared to liver)
Endoscopy
Meisner et al.16 PET/CT 370 MBq 50 min Visual
(uptake compared to liver)
Endoscopy, MRI, CT
enterography, small bowel
imaging
Löffler et al.15 PET 3–5 MBq/kg NR Visual and semiquantitative Endoscopy, abdominal
ultrasonography
Lemberg et al.14 PET 3.7 MBq/kg 45 min Visual (uptake compared
to spine)
Endoscopy, small bowel
follow-through
Neurath et al.13 PET 370 MBq 60 min Visual and semiquantitative Endoscopy, hydro-MRI,
immunoscintigraphy
Skehan et al.12 PET 1.85 MBq/kg 60 min Visual (uptake compared
to spine)
Endoscopy, small bowel
follow-through
Bicik et al.11 PET 220 MBq NR Visual and semi-quantitative Endoscopy
Legend: NR: not reported.
34918F-FDG-PET and IBDThere may be a role for 18F-FDG PET and PET/CT in the
initial evaluation of adult patients with suspected IBD. In
fact, these methods could be used to identify patients with
a chronic intestinal inflammation in association with clinical
history, physical examination, laboratory tests, other
imaging modalities and endoscopic evaluation.2,18,21,24,26,28
In particular, 18F-FDG PET and PET/CT may be useful when
endoscopic evaluation may not be feasible (for example in
some cases severe disease or strictures in the bowel may
prevent a complete endoscopic examination).2,20,28
In patientswith an established diagnosis of IBD, 18F-FDG PET
and PET/CT may provide information about disease activity,
location and extent within the intestinal tract, allowing early
recognition of disease relapse and possible complications of
the disease in association with clinical symptoms, physical
exam and laboratory data.2,13,16,17,19,20,22–26,28,29
As demonstrated by some studies, integrating 18F-FDG PET
with CT enterography21,23–25 or CT enteroclysis18 may allow
metabolic and morphologic assessment of disease activity.Furthermore, the diagnostic accuracy of 18F-FDG PET in the
assessment of IBD was superior compared to hydro-MRI13,29
and granulocyte scintigraphy with labeled antibodies.13
18F-FDG PET and PET/CT may guide decisions regarding the
choice of therapy.26 Thesemethodsmay be useful in identifying
preoperatively the presence or absence of significant inflam-
mation within the wall of an obstructive bowel segment.20
Functional methods may also allow the evaluation of
efficacy of the medical therapy in IBD, because metabolic
changes after the treatment (assessed by 18F-FDG PET)
usually precede morphological changes (assessed by conven-
tional imaging methods).22
Several studies demonstrated that 18F-FDG PET may be a
useful noninvasive tool for identifying and localizing active
intestinal inflammation also in children with IBD. Also if PET
may not be able to replace conventional studies, several
authors underlined that this functional method may be
useful when conventional studies cannot be performed or
fail to be completed.12,14,15,27
Table 3 Results of the quality assessment of the studies included in this systematic review.
First author and
year of publication
Spectrum of the patients Consecutive
recruitment of
the patients
Reference standard Ascertainment of the
gold standard
regardless of the
index test results
Blind comparison
of the index test
and reference
standard
Enough
explanation
of the index
test to permit
replication
2011 Oxford center for
evidence based medicine
level of evidence
(http://www.cebm.net/
index.aspx?o=5653)
Holtmann et al. 2012 Adult patients with proven CD Yes Endoscopy and
hydro-MRI
Yes Yes Yes 2
Lenze et al. 2012 Adult patients with proven
CD and known or suspected
intestinal stricture
Yes Endoscopy and tissue
biopsy
Yes Yes Yes 2
Däbritz et al. 2011 Pediatric patients with proven
diagnosis of IBD but unknown
activity of the disease
N/A Endoscopy and tissue
biopsy
Yes Yes Yes 3
Lapp et al. 2011 Adult patients with known or
suspicious IBD
No Endoscopy Yes Yes Yes 3
Shyn et al. 2010 Adults with known CD and
clinically suspected active
disease
No Endoscopy or surgery
with tissue biopsy
Yes Yes Yes 3
Ahmadi et al. 2010 Adult patients with established
or suspected IBD
No CT enterography in
combination of HBI
score, SIBDQ score,
CRP, ESR
Yes No Yes 4 (poor reference
standard)
Das et al. 2010 Adult patients with mild to
moderate active UC
N/A Endoscopy Yes Yes Yes 3
Spier et al. 2010 Adult patients with moderately
active IBD
No Physician global
assessment
scores
Yes Yes Yes 4 (poor reference
standard)
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Groshar et al. 2010 Adult patients with suspected
or proven active CD
Yes CT entrography Yes No Yes 4 (poor reference
standard)
Jacene et al. 2009 Adult patients with CD with
obstructive symptoms
No Surgery and tissue
biopsy
Yes Yes Yes 3
Rubin et al. 2009 Adults with the history of CD
in complete remission for at
least 6 months
N/A Endoscopy and tissue
biopsy
Yes N/A Yes 3
Das et al. 2007 Adult patients suspicious
for IBD
N/A Endoscopy and tissue
biopsy
Yes Yes Yes 3
Louis et al. 2007 Adult patients with proven
CD undergoing endoscopy
for medical reasons
Yes Endoscopy and tissue
biopsy
Yes Yes Yes 2
Meisner et al. 2007 Adult patients with proven
IBD and symptoms of disease
exacerbation
Yes Endoscopy or CT
enterography
Yes Yes Yes 2
Löffler et al. 2006 Pediatric patients with
suspected IBD
Yes Endoscopy and/or
tissue biopsy
and/or ultrasonography
Yes No Yes 3
Lemberg et al. 2005 Pediatric patients with newly
diagnosed IBD or known IBD
with symptoms suggestive
of active disease
No Endoscopy
(with tissue biopsy)
and/or contrast study
Yes Yes Yes 3
Neurath et al. 2002 Adult patients with proven
chronic active CD for at least
1 year duration
No Endoscopy in only
28/59 patients
Yes N/A Yes 3
Shekan et al. 1999 Children or adults with
suspected IBD
No Endoscopy and/or small
bowel follow through
Yes Yes No 3
Bicik et al. 1997 Patients with clinical and
endoscopic suspicion of IBD
N/A Endoscopy and tissue
biopsy
Yes No No 3
351
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Figure 2 Plot of individual studies and pooled sensitivity of 18F-FDG PET and PET/CT in detecting IBD on a per segment-based
analysis, including 95% confidence intervals (95%CI). The size of the circles indicates the weight of each study. Sensitivity of 18F-FDG
PET and PET/CT ranged from 70% to 100%, with pooled estimate of 85% (95%CI: 81–88%). The included studies were statistically
heterogeneous in their estimates of sensitivity (I-square: 79.7%).
352 G. Treglia et al.The role of 18F-FDG PET and PET/CT in the assessment of
IBD is promising but currently these diagnostic methods are
routinely used in patients with IBD only in centers with a
strong research presence in this area.3 Whether the
information derived from PET imaging justifies the additional
radiation exposure related to the radiopharmaceutical
administration requires additional investigation.3 Further-
more, larger clinical trials and cost-effectiveness studies
about the use of 18F-FDG PET and PET/CT in patients with IBD
are needed to strengthen the usefulness of these functional
imaging methods in this setting. Similarly, it is conceivable
that further developments of molecular imaging such as
hybrid PET/MRI will provide relevant information on IBD.30
3.3. Quantitative analysis (meta-analysis)
The diagnostic performance results of 18F-FDG PET and
PET/CT in the seven included studies in the meta-analysis
are presented in Figs. 2–4.
The sensitivity of 18F-FDG PET and PET/CT in detecting
IBD calculated on a per segment-based analysis ranged fromFigure 3 Plot of individual studies and pooled specificity of 18F-
analysis, including 95% confidence intervals (95%CI). The size of the
PET and PET/CT ranged from 55% to 97%, with pooled estimate o
heterogeneous in their estimate of specificity (I-square: 91.6%).70% to 100%, with pooled estimate of 85% (95%CI: 81–88%)
(Fig. 2). The included studies were statistically heteroge-
neous in their estimate of sensitivity (I-square: 79.7%).
The specificity of 18F-FDG PET or PET/CT in detecting IBD
calculated on a per segment-based analysis ranged from
55% to 97%, with pooled estimate of 87% (95%CI: 84–90%)
(Fig. 3). The included studies were statistically heteroge-
neous in their estimate of specificity (I-square: 91.6%).
The pooled LR+, LR− and DOR were 6.19 (95%CI: 2.86–
13.41), 0.19 (95%CI: 0.10–0.34), and 44.35 (95%CI: 11.77–
167.07), respectively. The area under the ROC curve was
0.933 (Fig. 4). There was not statistically significant threshold
effect in our study. Funnel plots of the included studies for
sensitivity and specificity showed some asymmetry demon-
strating a possible publication bias.
4. Discussion
To the best of our knowledge, this systematic review and
meta-analysis is the first to evaluate the diagnostic perfor-
mance of 18F-FDG PET or PET/CT in patients with IBD. SeveralFDG PET and PET/CT in detecting IBD on a per segment-based
circles indicates the weight of each study. Specificity of 18F-FDG
f 87% (95%CI: 84–90%) The included studies were statistically
Figure 4 Summary ROC curve of diagnostic accuracy of 18F-FDG
PET and PET/CT in patients with IBD on a per segment-based
analysis; the curves represent the summary ROC curve (middle)
and 95% confidence intervals. The area under the ROC curve was
0.933, demonstrating that 18F-FDG PET and PET/CT are accurate
methods in the diagnosis of IBD.
35318F-FDG-PET and IBDstudies have used 18F-FDG PET or PET/CT in patients with
suspected IBD reporting different values of sensitivity and
specificity. However, many of these studies have limited
power, analyzing only relatively small numbers of patients.
In order to derive more robust estimates of diagnostic
performance of 18F-FDG PET or PET/CT in patients with IBD
we pooled published studies. A systematic review process
was adopted in ascertaining studies, thereby avoiding
selection bias. Furthermore, the quality of the included
studies was assessed by using the 2011 Oxford Center for
Evidence-Based Medicine checklist for diagnostic studies
(Table 3).9
Pooled results of our meta-analysis indicate that 18F-FDG
PET and PET/CT demonstrate good sensitivity (85%) and good
specificity (87%) in assessing IBD on a per segment-based
analysis. Furthermore, the area under the ROC curve (0.933)
demonstrates that 18F-FDG PET and PET/CT are accurate
diagnostic methods in this setting.
Nevertheless, only seven studies are included in the
quantitative analysis and this could limit the statistical
power of our meta-analysis.
Heterogeneity between studies may represent a potential
source of bias. The included studies were statistically
heterogeneous in their estimates of sensitivity and specific-
ity. This heterogeneity is likely to arise through diversity in
methodological aspects between different studies (Table 2).
The baseline differences among the patients in the included
studies (Table 1) and the study quality (Table 3) may
have contributed to the observed heterogeneity of the
results too. However, such variability was accounted for in a
random effect model in our pooled analysis.
A limitation of our analysis is the lack of the calculation of
pooled sensitivity and specificity of 18F-FDG PET and PET/CTin different forms of IBD, for example CD vs. UC; the frequent
mixing of these forms of IBD in the patient population of
the included studies hampered the data extraction and the
separate calculation of diagnostic performance of 18F-FDG
PET and PET/CT in such groups.
In our meta-analysis, we chose to calculate pooled sensi-
tivity and specificity on a per segment-based analysis because
most of the authors have adopted this criterion. However,
we cannot exclude the potential bias derived from this
choice, but there were not sufficient data to obtain significant
results performing a per patient- or a per region-based pooled
analysis. Furthermore, it was not possible to perform a
sub-analysis comparing PET versus PET/CT results because of
insufficient data.
Publication bias is a major concern in all meta-analyses as
studies reporting significant findings are more likely to be
published than those reporting nonsignificant results. In-
deed, it is not unusual for small-sized early studies to report
a positive relationship that subsequent larger studies fail to
replicate. We assessed the publication bias in our analysis by
using funnel plots which showed some asymmetry, especially
for specificity pooling.
5. Conclusions
In patients with suspected IBD 18F-FDG PET and PET/CT
demonstrated good sensitivity and specificity. 18F-FDG PET
and PET/CT are accurate methods in this setting. Current-
ly, the literature focusing on the use of 18F-FDG PET or
PET/CT in IBD remains still limited; thus, further large
multicenter studies will be necessary to substantiate the
diagnostic accuracy of 18F-FDG PET and PET/CT in patients
with IBD.
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